I Love Lund Invests Heavily in Avidicare's Growth

In a strategic move to bolster its investment portfolio, I Love Lund AB has announced a substantial investment in Avidicare AB, a company renowned for its advanced ventilation solutions for operating rooms. By subscribing to 14,492,753 shares at 0.069 kronor each, I Love Lund has committed 1 million kronor to Avidicare's ongoing share issue. This investment places I Love Lund among Avidicare's top ten shareholders, holding approximately 3% of the outstanding shares post-issuance.

Avidicare is in the process of raising up to 26 million kronor, with over 20 million already secured. The capital will be directed towards the company's international expansion and commercialization efforts. Existing shareholders, including Industrifonden and Almi Invest, are participating in the round, alongside new investors like I Love Lund and several angel investors.

Avidicare's Opragon brand offers a comprehensive range of ventilation solutions, boasting over 350 systems delivered and supported by strong evidence from top universities. The company's efficient systems are designed to reduce infection risks while ensuring comfort and low operating costs. With a network of over fifteen distributors and several major technology partners, Avidicare is experiencing a surge in project inflow and quotations, setting a solid foundation for profitability with the new funding.

This investment marks I Love Lund's first venture in 2025, reflecting their confidence in Avidicare's future. As a local investment company, I Love Lund focuses on businesses with strong ties to Lund, primarily in early-stage growth companies with high innovation potential. The investment in Avidicare aligns with their strategy to support companies with capital, expertise, and networking opportunities.

Björn Englund, CEO of I Love Lund, expressed optimism about Avidicare's potential for rapid scaling, given its experienced team and proven sales strategy. Avidicare's CEO, Peter Höjerback, highlighted the value of I Love Lund's local network and expertise in facilitating international growth.

For investors, this partnership signals a promising opportunity. Avidicare's established product line and growing market presence, combined with the strategic backing from I Love Lund and other investors, suggest a strong growth trajectory. Considering these factors, the recommendation is to hold for now, monitoring the company's progress in achieving its expansion and profitability goals.